OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Alternatives to traditional freeze-drying may reshape biological development and the cold chain.
A clinical-stage company produces adeno-associated virus vectors in-house.
Manufacturing increases but future demand remains unpredictable.
April 21, 2021
Vertex and CRISPR have amended their collaboration agreement to include the development, manufacture, and commercialization of CTX001, an investigational CRISPR/Cas9-based gene editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia.
Post-inspection report reveals nine sanitary and process problems at Bayview, Md., facility.
CalAmp's new sensor for cold-chain applications provides visibility for shipping vaccines.
April 19, 2021
Pending a completed FDA inspection, Emergent BioSolutions halts manufacture of vaccine drug substance at Maryland facility.
CordenPharma’s expansion will include the addition of new production lines which will be merged into the lipid manufacturing process in April 2021.
April 16, 2021
Sartorius has expanded in the United Kingdom with the relocation to a new facility in Havant, Hampshire, for downstream processing equipment.
April 15, 2021
The new Abzena facility will initially include four modular suites with up to two 2000-L bioreactors, followed by the addition of two more 2000 L suites.
The ATMPS and Ori Biotech collaboration aims to improve visibility and reporting of cell and gene therapy manufacturing through a pre-integrated data solution.
April 13, 2021
Catalent’s new mammalian cell culture suites in Madison, Wis. use single-use bioreactor systems for CGMP clinical and commercial manufacturing.
April 08, 2021
The China National Medical Products Administration has given the company the green light to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its biologics facility in Guangzhou, China.